BRCA2‐Related Hereditary Cancer Syndrome‐Associated Small Bowel Adenocarcinoma With Multiple BRCA2 Mutations: A Case Report and Review of the Literature
ABSTRACT Background Small bowel adenocarcinomas (SBAs) are rare and aggressive cancers. About one‐fifth of SBA patients have predisposing conditions; among them, there are also genetic tumor syndromes, including Lynch syndrome, familial adenomatous polyposis, and Peutz‐Jeghers syndrome. Although BRC...
Saved in:
Published in | Cancer reports Vol. 8; no. 4; pp. e70200 - n/a |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.04.2025
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
ISSN | 2573-8348 2573-8348 |
DOI | 10.1002/cnr2.70200 |
Cover
Summary: | ABSTRACT
Background
Small bowel adenocarcinomas (SBAs) are rare and aggressive cancers. About one‐fifth of SBA patients have predisposing conditions; among them, there are also genetic tumor syndromes, including Lynch syndrome, familial adenomatous polyposis, and Peutz‐Jeghers syndrome. Although BRCA2 mutations, both somatic and germline, have been recently described in SBAs, direct evidence of BRCA2 inactivation in SBA tumor tissue of patients with BRCA2‐related hereditary cancer syndrome is still very limited.
Case Presentation
Herein, we described a case of a 51‐year‐old woman with a history of breast cancer who developed an adenocarcinoma of the duodeno‐jejunal flexure causing persistent vomiting. After clinical staging, the patient underwent surgical resection, and histologic examination of the specimen confirmed a poorly differentiated adenocarcinoma infiltrating the visceral peritoneum and showing lymph node metastases (stage III, pT4N1). Two years later, the SBA relapsed, and next generation sequencing was performed in matched tumor and normal tissues. In addition to KRAS and TP53 mutations in the tumor, both somatic and germline BRCA2 mutations were identified, indicating biallelic BRCA2 alterations.
Conclusion
BRCA2‐associated hereditary tumor syndrome could have an etio‐pathogenetic role in SBA development; thus, we suggest that this syndrome should be considered in patients with an SBA diagnosis below the age of 50 years, especially when a personal or family history of breast cancer is present. |
---|---|
Bibliography: | The authors received no specific funding for this work. Funding Francesca Antoci and Tommaso Colella are co‐first authors. ObjectType-Case Study-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Report-1 ObjectType-Article-1 ObjectType-Review-5 content type line 23 ObjectType-Case Study-4 ObjectType-Feature-2 ObjectType-Report-3 Funding: The authors received no specific funding for this work. |
ISSN: | 2573-8348 2573-8348 |
DOI: | 10.1002/cnr2.70200 |